848 related articles for article (PubMed ID: 25702254)
21. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
22. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
Marciano S; Galdame OA; Barcan LA; Gadano AC
Acta Gastroenterol Latinoam; 2015 Mar; 45(1):76-9. PubMed ID: 26076519
[TBL] [Abstract][Full Text] [Related]
24. Protease inhibitors for hepatitis C: economic implications.
Turner SJ; Brown J; Paladino JA
Pharmacoeconomics; 2013 Sep; 31(9):739-51. PubMed ID: 23839698
[TBL] [Abstract][Full Text] [Related]
25. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
26. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016].
Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B
Orv Hetil; 2017 Feb; 158(Suppl 1):23-35. PubMed ID: 28218868
[TBL] [Abstract][Full Text] [Related]
27. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
28. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
30. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
31. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
32. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 22 September 2017].
Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B
Orv Hetil; 2018 Feb; 159(Suppl 1):24-37. PubMed ID: 29478340
[TBL] [Abstract][Full Text] [Related]
33. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
34. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
35. Telaprevir for the treatment of chronic hepatitis C infection.
Muir AJ
Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
[TBL] [Abstract][Full Text] [Related]
36. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
37. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
38. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Pearlman BL
Lancet Infect Dis; 2012 Sep; 12(9):717-28. PubMed ID: 22647717
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Nair S; Lipscomb J; Eason J
Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
